Insider transactions

EDGAR

LIFECORE BIOMEDICAL, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–11 of 11

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-06-04 Filed 2026-06-08Kiper Christopher S Director · 10% ownerLegion Partners Asset Management, LLC Director · 10% ownerLegion Partners, L.P. I Director · 10% ownerLegion Partners, L.P. II Director · 10% ownerLegion Partners, LLC Director · 10% ownerLegion Partners Holdings, LLC Director · 10% ownerWhite Raymond T. Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,907——103,482Direct (D) No
F1, F4, F5, F6, F2, F3
  • F1 This Form 4 is filed jointly by Legion Partners, L.P. I (Legion Partners I), Legion Partners, L.P. II (Legion Partners II), Legion Partners, LLC (General Partner), Legion Partners Asset Management, LLC (Legion Partners Asset Management), Legion Partners Holdings, LLC (Legion Partners Holdings), Christopher S. Kiper and Raymond White (collectively, the Reporting Persons). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that owns more than 10% of Lifecore Biomedical, Inc.'s (the Issuer) outstanding shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  • F4 These securities are RSUs granted to Mr. Kiper, a member of the Issuer's Board of Directors (the Board) in respect of his service on the Board. Mr. Kiper holds these RSUs for the benefit of Legion Partners Asset Management. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions. As of the date hereof, 58,069 RSUs have vested.
  • F5 Mr. Kiper serves on the Board as a representative of Legion Partners Asset Management and its affiliates. Mr. Kiper does not have a right to any economic interest in securities of the Issuer granted to him by the Issuer in respect of his Board position, except to the extent of his role as a Managing Director of Legion Partners Asset Management. Legion Partners Asset Management is entitled to receive all of the economic interest in securities granted to Mr. Kiper by the Issuer in respect of Mr. Kiper's Board position. Mr. Kiper disclaims beneficial ownership of the Issuer's securities to which this report relates and at no time has Mr. Kiper had any economic interest in such securities except any indirect economic interest through Legion Partners Asset Management and its affiliates, entities in which Mr. Kiper has a controlling interest and investment control.
  • F6 The securities held by Mr. Kiper as described in footnotes (4) and (5) are securities in which Legion Partners Asset Management has all of the direct economic interest. Legion Partners Holdings is the sole member of Legion Partners Asset Management and each of Messrs. Kiper and White are Managing Directors of Legion Partners Asset Management. As a result of these relationships, Legion Partners Holdings and Messrs. Kiper and White may be deemed to beneficially own the securities owned directly by Legion Partners Asset Management.
  • F2 The restricted stock units (RSUs) convert into Common Stock of the Issuer on a 1 for 1 basis.
  • F3 Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Issuer first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Open filing 0000921895-26-001575 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05OBUS NELSON Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,907——164,100Direct (D) No
F1, F2
  • F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
  • F2 Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Open filing 0001017043-26-000002 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Antunes Humberto Calheiros Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,907——72,967Direct (D) No
F1, F2
  • F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
  • F2 Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Open filing 0001800145-26-000002 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Schechter Joshua Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,907——133,080Direct (D) No
F1, F2
  • F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
  • F2 Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Open filing 0001336601-26-000004 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Korenberg Matthew E Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,907——69,967Direct (D) No
F1, F2
  • F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
  • F2 Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Open filing 0001649903-26-000002 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Johnson Paul Harold Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,907——69,967Direct (D) No
F1, F2
  • F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
  • F2 Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Open filing 0002034858-26-000002 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Aryeh Jason Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,907——69,967Direct (D) No
F1, F2
  • F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
  • F2 Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Open filing 0001376960-26-000002 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05HOUDE LOVAS KATRINA Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)25,907——135,319Direct (D) No
F1, F2
  • F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
  • F2 Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Open filing 0001269294-26-000002 Read from the filing’s XML Dispute this row
2026-05-20 Filed 2026-05-21Josephs Paul Director · Officer: Chief Executive Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)40,4134.57
184,687.41

Derived: shares × price per share. Exact value 184687.41.

592,915Direct (D) No
F1
  • F1 Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting.
Open filing 0002022547-26-000003 Read from the filing’s XML Dispute this row
2026-04-14 Filed 2026-04-16Salus Thomas D. Officer: Chief Legal Administration
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)24,6455.20
128,154

Derived: shares × price per share. Exact value 128154.00.

246,333Direct (D) No
F1
  • F1 Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting.
Open filing 0002062209-26-000004 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-02Salus Thomas D. Officer: Chief Legal Administration
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)30,000——270,978Direct (D) No
F1, F2
  • F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
  • F2 Restricted Stock Units will vest on the 3rd anniversary of the grant date.
Open filing 0002062209-26-000002 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Greenhaven Road Investment Management, L.P. Common Stock, par value $0.001 per share7.62,868,881.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-008139 Dispute this row
MVM Funds LLC Common Stock, par value $0.001 per share7.62,868,881.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-008139 Dispute this row
Scott Miller Common Stock, par value $0.001 per share7.62,868,881.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-008139 Dispute this row
Greenhaven Road Capital Fund 1, L.P. Common Stock, par value $0.001 per share4.01,518,411.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-008139 Dispute this row
Greenhaven Road Capital Fund 2, L.P. Common Stock, par value $0.001 per share3.61,350,470.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 3Open filing 0000919574-26-008139 Dispute this row
Wynnefield Partners Small Cap Value, L.P. I Common Stock, $0.001 par value6.32,405,090.0009/27/2026 Filed 2026-09-29SCHEDULE 13D/AAmendment 11Open filing 0001104659-26-111939 Dispute this row
Wynnefield Partners Small Cap Value, L.P. Common Stock, $0.001 par value4.11,551,295.0009/27/2026 Filed 2026-09-29SCHEDULE 13D/AAmendment 11Open filing 0001104659-26-111939 Dispute this row
Wynnefield Small Cap Value Offshore Fund, Ltd. Common Stock, $0.001 par value2.71,024,376.0009/27/2026 Filed 2026-09-29SCHEDULE 13D/AAmendment 11Open filing 0001104659-26-111939 Dispute this row
Wynnefield Capital, Inc. Profit Sharing Money Purchase Plan Common Stock, $0.001 par value1.0367,350.0009/27/2026 Filed 2026-09-29SCHEDULE 13D/AAmendment 11Open filing 0001104659-26-111939 Dispute this row
Wynnefield Capital Management, LLC Common Stock, $0.001 par value10.33,956,385.0009/27/2026 Filed 2026-09-29SCHEDULE 13D/AAmendment 11Open filing 0001104659-26-111939 Dispute this row
Wynnefield Capital, Inc. Common Stock, $0.001 par value2.71,024,376.0009/27/2026 Filed 2026-09-29SCHEDULE 13D/AAmendment 11Open filing 0001104659-26-111939 Dispute this row
Nelson Obus Common Stock, $0.001 par value14.35,512,210.0009/27/2026 Filed 2026-09-29SCHEDULE 13D/AAmendment 11Open filing 0001104659-26-111939 Dispute this row
Joshua Landes Common Stock, $0.001 par value13.95,348,110.0009/27/2026 Filed 2026-09-29SCHEDULE 13D/AAmendment 11Open filing 0001104659-26-111939 Dispute this row
Legion Partners, L.P. I Common Stock, par value $0.001 per share15.96,376,738.0009/27/2026 Filed 2026-09-28SCHEDULE 13D/AAmendment 11Open filing 0000921895-26-002661 Dispute this row
Legion Partners, L.P. II Common Stock, par value $0.001 per share1.4537,406.0009/27/2026 Filed 2026-09-28SCHEDULE 13D/AAmendment 11Open filing 0000921895-26-002661 Dispute this row
Legion Partners, LLC Common Stock, par value $0.001 per share17.16,914,144.0009/27/2026 Filed 2026-09-28SCHEDULE 13D/AAmendment 11Open filing 0000921895-26-002661 Dispute this row
Legion Partners Asset Management, LLC Common Stock, par value $0.001 per share17.36,991,719.0009/27/2026 Filed 2026-09-28SCHEDULE 13D/AAmendment 11Open filing 0000921895-26-002661 Dispute this row
Legion Partners Holdings, LLC Common Stock, par value $0.001 per share17.36,991,919.0009/27/2026 Filed 2026-09-28SCHEDULE 13D/AAmendment 11Open filing 0000921895-26-002661 Dispute this row
Kiper Christopher S Common Stock, par value $0.001 per share17.36,991,919.0009/27/2026 Filed 2026-09-28SCHEDULE 13D/AAmendment 11Open filing 0000921895-26-002661 Dispute this row
White Raymond T. Common Stock, par value $0.001 per share17.36,991,919.0009/27/2026 Filed 2026-09-28SCHEDULE 13D/AAmendment 11Open filing 0000921895-26-002661 Dispute this row
BlackRock, Inc. Common Stock5.42,010,54606/30/2026 Filed 2026-07-29SCHEDULE 13GOpen filing 0002012383-26-002896 Dispute this row
Legion Partners, L.P. I Common Stock, par value $0.001 per share15.66,196,557.0006/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 10Open filing 0000921895-26-001747 Dispute this row
Legion Partners, L.P. II Common Stock, par value $0.001 per share1.4520,263.0006/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 10Open filing 0000921895-26-001747 Dispute this row
Legion Partners, LLC Common Stock, par value $0.001 per share16.96,716,820.0006/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 10Open filing 0000921895-26-001747 Dispute this row
Legion Partners Asset Management, LLC Common Stock, par value $0.001 per share17.16,794,395.0006/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 10Open filing 0000921895-26-001747 Dispute this row
Legion Partners Holdings, LLC Common Stock, par value $0.001 per share17.16,794,595.0006/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 10Open filing 0000921895-26-001747 Dispute this row
Kiper Christopher S Common Stock, par value $0.001 per share17.16,794,595.0006/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 10Open filing 0000921895-26-001747 Dispute this row
White Raymond T. Common Stock, par value $0.001 per share17.16,794,595.0006/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 10Open filing 0000921895-26-001747 Dispute this row
22NW Fund, LP Common Stock, par value $0.001 per share6.742,712,47206/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-294951 Dispute this row
22NW, LP Common Stock, par value $0.001 per share6.742,712,47206/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-294951 Dispute this row
22NW Fund GP, LLC Common Stock, par value $0.001 per share6.742,712,47206/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-294951 Dispute this row
22NW GP, Inc. Common Stock, par value $0.001 per share6.742,712,47206/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-294951 Dispute this row
Aron R. English Common Stock, par value $0.001 per share6.742,712,47206/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-294951 Dispute this row
Bryson O. Hirai-Hadley Common Stock, par value $0.001 per share058306/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-294951 Dispute this row
Nathaniel Calloway Common Stock, par value $0.001 per share0006/30/2026 Filed 2026-07-02SCHEDULE 13D/AAmendment 8Open filing 0001193125-26-294951 Dispute this row
BlackRock, Inc. Common Stock4.981,867,91603/31/2026 Filed 2026-04-27SCHEDULE 13G/AAmendment 1Open filing 0002012383-26-001749 Dispute this row
BlackRock, Inc. Common Stock5.11,899,90312/31/2025 Filed 2026-01-21SCHEDULE 13GOpen filing 0002012383-26-000770 Dispute this row
BlackRock, Inc. Common Stock4.91,834,31909/30/2025 Filed 2025-10-17SCHEDULE 13G/AAmendment 1Open filing 0002012383-25-002878 Dispute this row
BlackRock, Inc. Common Stock5.01,868,50306/30/2025 Filed 2025-07-17SCHEDULE 13GOpen filing 0002052113-25-003213 Dispute this row
22NW Fund, LP Common Stock, par value $0.001 per share11.14,367,49912/23/2024 Filed 2024-12-26SCHEDULE 13D/AAmendment 6Open filing 0000950170-24-140227 Dispute this row
22NW, LP Common Stock, par value $0.001 per share11.14,367,49912/23/2024 Filed 2024-12-26SCHEDULE 13D/AAmendment 6Open filing 0000950170-24-140227 Dispute this row
22NW Fund GP, LLC Common Stock, par value $0.001 per share11.14,367,49912/23/2024 Filed 2024-12-26SCHEDULE 13D/AAmendment 6Open filing 0000950170-24-140227 Dispute this row
22NW GP, Inc. Common Stock, par value $0.001 per share11.14,367,49912/23/2024 Filed 2024-12-26SCHEDULE 13D/AAmendment 6Open filing 0000950170-24-140227 Dispute this row
Aron R. English Common Stock, par value $0.001 per share11.14,367,49912/23/2024 Filed 2024-12-26SCHEDULE 13D/AAmendment 6Open filing 0000950170-24-140227 Dispute this row
Bryson O. Hirai-Hadley Common Stock, par value $0.001 per share058312/23/2024 Filed 2024-12-26SCHEDULE 13D/AAmendment 6Open filing 0000950170-24-140227 Dispute this row
Nathaniel Calloway Common Stock, par value $0.001 per share034,31512/23/2024 Filed 2024-12-26SCHEDULE 13D/AAmendment 6Open filing 0000950170-24-140227 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,741,977 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015158,359
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to LIFECORE BIOMEDICAL, INC.